Dutch guidelines for economic evaluation: 'from good to better' in theory but further away from pharmaceuticals in practice?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Quality of Life and Societal Costs Related to Celiac Disease Before and After Diagnosis.Clinical and translational gastroenterology · 2026
   Article
2. HiMSC and EV derived treatments increase Quality of Life and reduce amount of Knee Replacement Surgeries compared to current standard of care for knee osteoarthritis patients in The Netherlands.PloS one · 2026
   Article
3. Good Practices for Health Technology Assessment Guideline Development: A Report of the Health Technology Assessment International, HTAsiaLink, and ISPOR Special Task Force.International journal of technology assessment in health care · 2025
   Article
4. The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands.The European journal of health economics : HEPAC : health economics in prevention and care · 2024
   Article
5. Pharmaceutical pricing in Europe: time to take the right direction.Internal and emergency medicine · 2022
   Article
6. Do European pharmacists really have to trespass on medicine?The European journal of health economics : HEPAC : health economics in prevention and care · 2021
   Article
7. HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?The European journal of health economics : HEPAC : health economics in prevention and care · 2020
   Article
8. Comment on: 'NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence'.PharmacoEconomics · 2020
   Article
9. Health technology assessment for pharmaceutical regulation in the European Union: do we need another body?Journal of the Royal Society of Medicine · 2020
   Article
10. Comment on: 'The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study'.PharmacoEconomics · 2019
    Article
11. Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis.Orphanet journal of rare diseases · 2019
    Article
12. Conflict of interest disclosure: striking a balance?The European journal of health economics : HEPAC : health economics in prevention and care · 2019
    Article
13. Pharmaceutical pricing conundrum: time to get rid of it?The European journal of health economics : HEPAC : health economics in prevention and care · 2018
    Article
14. Hospital Pharmacists in Europe: Between Warehouse and Prescription Pad?PharmacoEconomics - open · 2018
    Article
15. Does Childhood Cochlear Implantation Spill Over to Carers' Employment Status?Ear and hearing
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as